Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120395 | 0.81 | ATM (0.44) | L3MBTL1ATMCYP19A1SIGMAR1MAOB | |
| SCHEMBL7154660 | 0.80 | MAOB (0.47) | L3MBTL1ATMCYP19A1KMT2AMAOB | |
| SCHEMBL7118017 | 0.76 | PPIB (0.43) | L3MBTL1ATMCYP19A1MAOBNPC1 | |
| SCHEMBL15346163 | 0.74 | ATM (0.48) | L3MBTL1ATMSIGMAR1MAOBNPC1 | |
| SCHEMBL30576331 | 0.74 | ATM (0.48) | L3MBTL1ATMSIGMAR1MAOBNPC1 | |
| SCHEMBL28862097 | 0.71 | CYP19A1 (0.40) | L3MBTL1CYP19A1SIGMAR1KMT2ANPC1 | |
| SCHEMBL27282516 | 0.69 | SMN1; SMN2 (0.48) | L3MBTL1ATMSIGMAR1KMT2AMAOB | |
| SCHEMBL28387593 | 0.69 | ALDH1A1 (0.54) | CYP19A1MAOBHTR2C | |
| SCHEMBL30065841 | 0.69 | ALDH1A1 (0.60) | ATMSIGMAR1MAOBNPC1MAPT | |
| SCHEMBL544297 | 0.69 | ALDH1A1 (0.60) | ATMSIGMAR1MAOBNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542871-A1 | METHOD FOR MAKING PRINTING PLATE BY INKJET DEPOSITION ON POSITIVE-WORKING MEDIA | Creo SRL (CA) | 2005-06-22 | — | — | EP | claimed |
| WO-2004007200-A1 | METHOD FOR MAKING PRINTING PLATE BY INKJET DEPOSITION ON POSITIVE-WORKING MEDIA | CREO SRL (CA) | 2004-01-22 | — | — | WO | claimed |
| US-20180132516-A1 | POSITIVE ALLOSTERIC MODULATORS OF SWEET TASTE | SENSORYGEN INC (US) | 2018-05-17 | — | — | US | disclosed |
| US-20100048494-A1 | Natural Products from Vinca | RICE UNIVERSITY (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048494-A1 | Natural Products from Vinca | HIRA, RDX, SLC22A8 | L3MBTL1 4275/4885ATM 4622/4885CYP19A1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.